Aethlon Medical Stock Forecast, Price & News

-0.14 (-2.61 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume849,222 shs
Average Volume3.13 million shs
Market Capitalization$63.32 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AEMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Aethlon Medical and its competitors with MarketBeat's FREE daily newsletter.

Aethlon Medical logo

About Aethlon Medical

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.26 out of 5 stars

Medical Sector

903rd out of 2,100 stocks

Surgical & Medical Instruments Industry

87th out of 174 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aethlon Medical (NASDAQ:AEMD) Frequently Asked Questions

Is Aethlon Medical a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aethlon Medical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aethlon Medical stock.
View analyst ratings for Aethlon Medical
or view top-rated stocks.

What stocks does MarketBeat like better than Aethlon Medical?

Wall Street analysts have given Aethlon Medical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aethlon Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aethlon Medical's next earnings date?

Aethlon Medical is scheduled to release its next quarterly earnings announcement on Thursday, June 24th 2021.
View our earnings forecast for Aethlon Medical

How were Aethlon Medical's earnings last quarter?

Aethlon Medical, Inc. (NASDAQ:AEMD) issued its earnings results on Tuesday, February, 9th. The medical equipment provider reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.05. The medical equipment provider had revenue of $0.63 million for the quarter.
View Aethlon Medical's earnings history

How has Aethlon Medical's stock price been impacted by Coronavirus (COVID-19)?

Aethlon Medical's stock was trading at $1.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AEMD stock has increased by 162.3% and is now trading at $5.22.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AEMD?

2 brokers have issued twelve-month price objectives for Aethlon Medical's stock. Their forecasts range from $5.00 to $11.00. On average, they expect Aethlon Medical's share price to reach $8.00 in the next year. This suggests a possible upside of 53.3% from the stock's current price.
View analysts' price targets for Aethlon Medical
or view top-rated stocks among Wall Street analysts.

Who are Aethlon Medical's key executives?

Aethlon Medical's management team includes the following people:
  • Dr. Charles J. Fisher Jr., CEO, Director & Member of Extracorporeal Therapy Advisory Board (Age 74, Pay $124k)
  • Mr. James B. Frakes, CFO, Sr. VP of Fin. & Sec. (Age 64, Pay $354.75k)
  • Mr. Guy F. Cipriani BS (Eng.), MBA, Sr. VP, Chief Bus. Officer & Director (Age 50, Pay $34k)
  • Mr. Sunil Sawhney, Head of Clinical Studies
  • Mr. Steven P. Larosa, Chief Medical Officer
  • Dr. Richard H. Tullis, Consultant (Age 76)

Who are some of Aethlon Medical's key competitors?

What other stocks do shareholders of Aethlon Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aethlon Medical investors own include Amarin (AMRN), Nokia (NOK), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), CRISPR Therapeutics (CRSP), Novavax (NVAX), OrganiGram (OGI), AT&T (T) and Aurora Cannabis (ACB).

What is Aethlon Medical's stock symbol?

Aethlon Medical trades on the NASDAQ under the ticker symbol "AEMD."

Who are Aethlon Medical's major shareholders?

Aethlon Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.52%), Northern Trust Corp (0.18%), Virtu Financial LLC (0.16%), First Midwest Bank Trust Division (0.13%), Millennium Management LLC (0.12%) and Citadel Advisors LLC (0.12%).
View institutional ownership trends for Aethlon Medical

Which major investors are buying Aethlon Medical stock?

AEMD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtu Financial LLC, First Midwest Bank Trust Division, Millennium Management LLC, Citadel Advisors LLC, Citadel Advisors LLC, and Northern Trust Corp.
View insider buying and selling activity for Aethlon Medical
or or view top insider-buying stocks.

How do I buy shares of Aethlon Medical?

Shares of AEMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aethlon Medical's stock price today?

One share of AEMD stock can currently be purchased for approximately $5.22.

How much money does Aethlon Medical make?

Aethlon Medical has a market capitalization of $63.32 million and generates $650,000.00 in revenue each year. The medical equipment provider earns $-6,390,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis.

How many employees does Aethlon Medical have?

Aethlon Medical employs 8 workers across the globe.

What is Aethlon Medical's official website?

The official website for Aethlon Medical is

Where are Aethlon Medical's headquarters?

Aethlon Medical is headquartered at 9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA, 92123.

How can I contact Aethlon Medical?

Aethlon Medical's mailing address is 9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-459-7800 or via email at [email protected]

This page was last updated on 6/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.